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Abstract | Since the launch of our journal as Nature Clinical Practice Neurology in 2005, we 
have seen remarkable progress in many areas of neurology research, but what does the 
future hold? Will advances in basic research be translated into effective disease-modifying 
therapies, and will personalized medicine finally become a reality? For this special Viewpoint 
article, we invited a panel of Advisory Board members and other journal contributors to 
outline their research priorities and predictions in neurology for the next 10 years. 
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Pain 
Ralf Baron 
Research over the past decade has unravelled a variety of independently operating pain mechanisms, 
but our patients have not yet seen the fruits of this endeavour, and approval of new pain medications is 
rare. One reason for this state of affairs is the obvious heterogeneity of pain mechanisms. Thus, the 
potential of novel compounds addressing specific therapeutic targets is often obscured if a 
heterogeneous group of patients is included in trials that evaluate the average pain reduction for the 
entire cohort. The next decade will see dramatic changes in trial design, and in the clinical 
management of patients with pain. 
When designing clinical trials, identification of the responding patient is an important factor. A 
complex cornucopia of clinical characteristics, including psychosocial factors, comorbidities, sensory 
abnormalities, and pathophysiological mechanisms, are likely to influence the overall response to pain 
treatment,1,2 and the specific clinical response pattern depends on the drug or intervention used.3 
Statistical modelling of treatment response, using data from existing and new trials, should reveal 
certain clinical baseline profiles that will increase the likelihood of response. Knowledge about 
predictive pathophysiological mechanisms will, consequently, be translated back into basic research. 
Relevant outcome parameters must also be determined. A commonly used end point in trials and in 
the clinic is the change in pain intensity averaged over the past 3 days. In reality, however, patients 
experience a complex temporal pattern of painful sensations. Some individuals perceive only a few 
severely painful attacks per day, in others the pain depends on movement, and often there are pain-free 
periods during the night. How can a patient calculate an average of these sensations over 3 days? 
Alternative outcome parameters that capture the individual pain-related quality of life and 
functionality need to be developed to account for the complex perception of pain and its consequences 
a precisely as possible. 
For shared decision-making between patients and physicians, and in light of shrinking health 
resources, careful evaluation of the risks and benefits of pain management is a prerequisite. The above 
approaches will help us to successfully implement the individualization of pain therapy. 
Child neurology 
Donna Ferriero 
We are witnessing an illuminating period in child neurology, and discoveries abound that will inform 
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practice and research for the next decade. The past 10 years saw the advent of therapeutic hypothermia 
for neonatal encephalopathy, and the results have been sufficiently enough to make this approach the 
standard of care in this scenario.4 However, the protection afforded by therapeutic hypothermia is not 
complete, so the search for adjuvant therapies continues. The addition of erythropoietin to therapeutic 
hypothermia has shown promising results in early clinical trials, especially for perinatal stroke.5 The 
use of stem cells represents another potential avenue to treat neonatal encephalopathy, and is being 
tested in pilot studies.6 Cell-based therapies have also been used to correct inborn errors of 
metabolism, such as lysosomal storage diseases.7 
Precision medicine will pave the way for more appropriate and targeted therapies in the next decade. 
De novo and rare inherited copy number variations (CNVs) are recognized to underlie the clinical 
manifestations of a growing list of neurodevelopmental conditions. For example, genome-wide 
analysis in cerebral palsy—not traditionally thought to be genetically determined—has uncovered a 
large number of chromosomal abnormalities associated with the disease.8 These findings were 
substantiated in a recent study, which determined the impact of de novo CNVs on the diagnosis and 
classification of cerebral palsy.9 
Similarly promising results have been obtained in other neurological conditions, including epileptic 
encephalopathies. The Epilepsy Phenome/Genome Project used exome-based sequence data to 
highlight novel candidate genes related to infantile spasms and Lennox–Gastaut syndrome.10 Our 
understanding of the clinically heterogeneous neuromuscular disorders, such as the congenital 
muscular dystrophies, has also benefited from unbiased genomic approaches.11 
A combined CNV and single-nucleotide variant data approach is expediting the discovery of new 
syndromes and genes involved in neuropsychiatric diseases associated with developmental delay, 
despite considerable genetic heterogeneity.12 Perhaps the disease that has benefited most from novel 
technologies is autism: both de novo missense mutations and de novo likely gene-disrupting (LGD) 
mutations contribute to diagnosis.13 
The next decade will be about leveraging the knowledge buried in genomics to define the causes of 
and treatments for paediatric neurological diseases. 
Alzheimer disease 
Giovanni B. Frisoni 
If you wish to know where you are going, first ask yourself where you are coming from. A decade 
ago, patients with cognitive complaints typically consulted me after 3.5 years of cognitive symptoms, 
and diagnosis of Alzheimer disease (AD) was largely based on structural imaging (CT or MRI) to rule 
out secondary causes. Biomarkers such as cortical hypometabolism on 18F-FDG–PET, hippocampal 
atrophy on MRI, and cerebrospinal fluid (CSF) biomarkers (amyloid-β42 and tau) were reserved for the 
few with early symptoms or an unclear clinical picture. The typical patient diagnosed with AD had a 
mean Mini-Mental State Examination (MMSE) score of 20/30, treatment was based on symptomatic 
drugs only, and disappointment was still raging about the dramatic failure of AN1792, the first 
candidate AD modifier.14 
My typical patient of 2015 has a history of cognitive complaints of 12 months or less. In my 
academic memory clinics, I use imaging and CSF biomarkers for most patients. In the context of real-
life diagnostic research studies, I include quantitated and automated imaging biomarker readouts in the 
clinical reports (18F-FDG–PET metrics of cortical hypometabolism, automated hippocampal volume 
extraction algorithms),15 and I have access to molecular imaging biomarkers that allow in vivo 
neuropathological analysis (for example, amyloid PET).16 Patients diagnosed with AD typically have 
an MMSE score of 25–26/30 and little or no disability, and all are given symptomatic drugs and are 
usually enrolled in clinical trials of second-generation anti-amyloid or anti-tau disease modifiers, some 
of which are providing early indications of effectiveness.17,18 
In 2025, I expect that early diagnosis of AD with molecular (imaging and CSF) biomarkers will be 
daily practice in all memory clinics worldwide, and patients will be prescribed a cocktail of drugs 
aimed at both improving symptoms and delaying disease progression. The main efforts, however, will 
be directed towards asymptomatic people with the molecular signature of AD (brain amyloidosis or 
tau).19 These individuals will be screened in the population with blood and genetic biomarkers,20–22 and 
will be treated with disease modifiers to prevent the onset of cognitive symptoms and disability. This 
well-known disease-prevention paradigm is analogous to the treatment of hypertension and 
hypercholesterolaemia to prevent cardiovascular and cerebrovascular events. 
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The toughest challenge will be to promote brain health by changing lifestyles in the population. An 
impressive amount of evidence indicates that physical activity has multiple benefits for vascular, 
cognitive and emotional health;23,24 however, people are reluctant to take up running, swimming or 
cycling for the sake of health alone. Scientists should stop advocating the need for yet another clinical 
trial on the cognitive benefits of healhy lifestyles,23 and lobby decision-makers to implement societal 
policies to actively promote these lifestyles. This approach will substantially benefit not only the brain, 
but also society overall. 
Neuro-oncology 
Chetan Bettegowda & Ziya L. Gokaslan 
The past decade has seen an explosion in the understanding of the molecular and genetic basis of 
dozens of tumour types, ignited by advances in our ability to study systems at a global level, and at an 
unprecedented pace. For many tumour types, our improved knowledge of the tumour–host interaction, 
the critical pathways that lead to tumorigenesis, and the mechanisms that underlie treatment response 
and resistance have led to the development of new therapies, including those that modulate the 
immune system or target specific genetic alterations. These discoveries have led to dramatic 
improvements in outcomes for a number of cancer types. Unfortunately, although the scientific 
advances in neuro-oncology have kept pace with those in other areas of oncology, the translation of 
this knowledge has been slow to improve patient outcomes. 
Median survival for glioblastoma, the most common brain cancer, remains measured in months, with 
nearly all patients eventually succumbing to the disease. There is a dearth of FDA-approved therapies 
for nearly all CNS malignancies. One factor in our inability to adequately treat these tumours is the 
failure of historical classification methods to appreciate their complexity. Within any broad category 
of cancers affecting the CNS, genetic, epigenetic and proteomic profiling has revealed the existence of 
multiple subtypes.25 These molecular characteristics can be predictive and prognostic, and have 
already begun to guide treatment selection in certain patient populations, such as SMO inhibitors in 
SHH-driven medulloblastoma, and tyrosine kinase inhibition in BRAF-mutant gliomas.26,27 
In the next 10 years, we anticipate that the pathological diagnosis of CNS tumours will incorporate 
routine comprehensive molecular characterization. The knowledge derived from such detailed 
investigations of tumour specimens will enable significant advances, providing the basis for novel 
therapeutic and diagnostic strategies. CNS malignancies fall into the category of rare diseases, with 
each affecting only a few thousand individuals around the world, making appropriate clinical trials 
difficult to conduct. Grouping of patients into well-curated populations that are comparable at the 
subcellular level will allow the execution of clinical trials in populations that are most likely to benefit. 
These advances will, hopefully, lead to the improvements in survival that we are all so desperate to 
witness. 
Regenerative neurology 
John A. Kessler 
The field of neurological therapeutics has blossomed over the past decade, with therapies that can both 
prevent disease progression and treat symptoms, but at present no techniques are available for 
regenerating the damaged nervous system. The next decade will witness the advent of regenerative 
neurology, a broad term that encompasses regeneration, replacement and/or engineering of cells to 
restore normal nervous system function. This change will reflect the convergence of advances in stem 
cell biology, gene therapy, materials science and nanotechnology, and gene-editing techniques (for 
example, the TALENS and CRISPR–Cas9 gene-editing platforms).28,29 
Clinical trials of different types of stem cells have already commenced for neurological disorders 
including spinal cord injury, stroke, amyotrophic lateral sclerosis, multiple sclerosis, several genetic 
enzyme deficiencies, and other diseases.30,31 Similarly, numerous gene therapy trials have been 
conducted for a spectrum of disorders, including Parkinson disease, brain tumours, diabetic 
neuropathy, genetic enzyme deficiencies, and Alzheimer disease.32–34 
Although these early trials might demonstrate some clinical benefits, their efficacy will be limited by 
both technical and biological constraints, and strategies that combine new technologies are likely to be 
required. For example, stem cells require a highly regulated microenvironment, or ‘niche’, to survive, 
differentiate and integrate—an issue that is not addressed by current trials. Biomaterials can be 
designed to promote transplant survival and integration, both by providing the necessary cell–matrix 
interactions and through localized delivery of drugs or proteins.35,36 Convergent technologies will be 
 4 
required to explore the potential of RNA interference or short hairpin RNAs to knock down levels of 
mutant proteins in inherited neurological diseases37 or, even more remarkably, to correct the defective 
gene sequences via gene-editing techniques.28,29 This effort will require new vectors—both viral and 
nonviral—that are being developed to overcome the problems that have impeded gene therapy to 
date.32,33 The advent of such combinatorial approaches in the next decade will help to launch a new era 
of regenerative neurology. 
Epilepsy 
Annamaria Vezzani 
Epilepsy is a devastating neurological disease that afflicts approximately 1% of the world’s 
population. Over the past 10 years, working as a basic scientist in the field of experimental epilepsy, I 
have witnessed the emergence of important new knowledge related to the basic mechanisms of the 
generation and recurrence of epileptic seizures—the main hallmark of epilepsy. Studies in animal 
models and in vitro brain cell and slice preparations have been instrumental in deepening our 
understanding of the molecules and pathways involved in the pathogenesis of seizures, and in the 
adaptive changes that the brain undergoes to re-establish homeostasis and promote repair.38,39 These 
mechanisms represent an invaluable source of potential targets for drug and biomarker discovery. 
Unfortunately, the development of new therapies lags behind the advances in basic research. In 
around 40% of people with epilepsy, the seizures cannot be controlled by the available antiepileptic 
drugs (AEDs). Even in responsive patients, the AEDs mainly provide symptomatic control of seizures, 
and often produce serious adverse effects.40,41 Next-generation therapies need to have disease-
modifying properties to halt or reverse the progression of epilepsy, or to prevent its onset in 
susceptible individuals. This unmet clinical need represents a translational research priority for the 
next decade. In addition, an intensive search is underway for EEG, imaging and circulating biomarkers 
of epilepsy onset and prognosis, and for prediction of the therapeutic effects of drugs.42,43 The 
availability of biomarkers will be instrumental in the development of a new generation of therapies 
that are better targeted to the brain pathological processes in people who have epilepsy or are at high 
risk of developing the disease. 
In the coming years, substantial efforts will be devoted to addressing the pathogenic mechanisms 
underlying comorbidities such as cognitive deficits, depression and autism spectrum disorders, which 
severely affect quality of life in people with epilepsy, especially those in the paediatric population.44 In 
the context of preclinical research, it will be critical to refine animal models of adult and paediatric 
epilepsies to improve biomarker validation and drug discovery.45 In addition, novel approaches are 
being developed, including the use of simple model organisms such as zebrafish (Danio rerio) to 
model acute seizures and genetic epilepsies,46 and the generation of patient-specific neurons through 
induced pluripotent stem cell reprogramming to facilitate the development of cell-based novel drugs.47 
Finally, technological improvements in diagnostic and research tools are ongoing. These include 
more-sophisticated EEG recording modalities for monitoring and predicting seizures in patients, 
optogenetic-based approaches for halting seizures, new devices for delivering drugs on demand, and 
improved and novel noninvasive molecular brain imaging approaches.40,48–51 This armamentarium, 
together with increasingly sensitive and informative ‘omics’ and genetic approaches,52,53 will help us 
not only to increase our knowledge of this multifaceted and complex disease, but also to markedly 
improve the therapeutic options for patients. 
Channelopathies 
Stephen G. Waxman 
The prototypical antiepileptic medication phenytoin was discovered nearly a century ago. When 
phenytoin was introduced into clinical practice, its mode of action was not understood, but we now 
know that it acts, in large part, by blocking sodium channels. Since the advent of phenytoin, a stream 
of additional compounds that target ion channels have been developed. 
Over the past decade, the pace of progress has quickened. A remarkable convergence of genetics, 
ion channel biology and neurology has yielded dramatic and far-reaching advances in our 
understanding of ion channels and their roles in human disease. Ion channels are increasingly being 
implicated in epileptiform disorders, and sodium channels have been shown to have important 
pathogenetic roles in disorders including myotonias and periodic paralyses, migraine, and peripheral 
neuropathy.54–58 Studies on channelopathies—disorders caused by mutations in genes encoding 
specific ion channels—have firmly established a role for sodium channels such as NaV1.7 (encoded by 
 5 
SCN9A) as central players in human pain.59 In concert, therapeutic molecules that block specific 
subtypes of sodium channels while sparing others are under development.60 Advanced techniques for 
atomic-level molecular modelling,61 together with the solution of the crystal structure of prototypical 
bacterial sodium channels, have propelled molecular pharmacology to new levels. 
The next decade promises to be even more exciting. In my opinion, we are likely to see rapid 
translation of these advances into the therapeutic realm. I predict that within the next 10 years, new, 
more-effective therapies for pain that target ‘peripheral’ molecules such as the sodium channels 
NaV1.7, NaV1.8 and NaV1.9 will enter the clinical domain. Given that the target molecules are crucial 
for electrogenesis in peripheral pain-signalling neurons but have little, if any, role in the brain, these 
new pain medications should not affect the brain and, thus, will not have central adverse effects such 
as sedation, confusion, ataxia or diplopia, and will not have addictive potential. I also anticipate that 
new genomically guided approaches to chronic pain, in which medications are matched to the genomic 
make-up of the patient, will transform pain management from ‘trial and error’ to ‘first time around’. 
Finally, I believe that additional channelopathies of the nervous system are likely to soon be 
discovered soon. Evidence is emerging that NaV1.8 sodium channels, which are not normally present 
within the cerebellum, are expressed by Purkinje neurons in patients with multiple sclerosis (MS).62 
This anomalous expression leads to mistuning of these critically important cerebellar output neurons, 
which in turn leads to clinical dysfunction. Experiments in animal models have already demonstrated 
that some of the symptoms produced by this channelopathy can be ameliorated by blocking the 
offending molecules.63 Hopefully, these findings will provide a basis for development of new targeted 
therapies for MS. 
Autoantibody-related disorders 
Sven Jarius & Brigitte Wildemann 
Over the past 10 years, we have witnessed the discovery of numerous autoantibody-related 
neurological disorders, and the field is still growing. Of particular importance was the identification of 
aquaporin-4 (AQP4), the most abundant water channel in the CNS, as an antibody target in patients 
with neuromyelitis optica spectrum disorders (NMOSD) and its formes frustes,64 and the discovery of 
N-methyl-D-aspartate receptors (NMDARs) and the voltage-gated potassium channel (VGKC) 
complex proteins LGI1 and CASPR2 as antigens in limbic encephalitis.65 
Testing for AQP4-IgG is of the utmost importance in the differential diagnosis of multiple sclerosis 
(MS), particularly if optic neuritis, myelitis (mostly longitudinally extensive) and/or brainstem 
encephalitis are present, as some treatments that have been shown to be beneficial in MS—for 
example, IFN-β, natalizumab and fingolimod—are considered to be ineffective or even detrimental in 
AQP4 encephalomyelitis. The availability of NMDAR-IgG and VGKC-complex-IgG testing has made 
it possible to identify patients with encephalitis who are likely to respond to immunotherapy. 
In AQP4 and NMDAR encephalomyelitides, a direct pathogenic role of the respective antibodies is 
highly likely, and the therapeutic and prognostic implications have been formally demonstrated.66,67 
By contrast, the pathogenic impact of other antibodies with high differential diagnostic potential still 
needs to be studied in more detail. Further anti-neuronal reactivities identified over the past 10 years 
include, among others, antibodies to AMPAR, GABABR, GABAAR, glycine receptors, mGluR5 and 
DPPX in encephalitis; ITPR1, Homer-3, CARP, PKCγ, and ARHGAP26 in cerebellitis (termed 
‘Medusa head ataxia’68); MUSK and LRP-4 in myasthenia gravis; and CASPR2 in neuromyotonia. 
Moreover, a new role in anti-AQP4-negative myelitis and optic neuritis was recently assigned to anti-
myelin oligodendrocyte glycoprotein antibodies.69 
These findings have substantially facilitated the laboratory diagnosis of neurological autoimmune 
disorders. However, the rapid increase in numbers of potentially useful antibody markers also presents 
considerable diagnostic challenges. Currently, a multitude of commercial and in-house assays are 
used, some of which might be insufficiently sensitive and/or specific.70 Given the potentially dramatic 
therapeutic consequences of false test results, future research should focus not only on identifying new 
antibody markers, but also on developing highly standardized immunoassays. In this context, 
emphasis needs to be placed on implementation of regular (international) inter-laboratory comparison 
trials for the most important novel autoantibodies, as well on creating the necessary institutional 
structures to perform such trials in a manufacturer-independent fashion. 
A particular threat lies in the discrepancy between the low prevalence of many of the newly 
described autoantibodies and the high number of tests requested in daily practice by physicians who 
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wish to offer their patients the most extensive diagnostic work-up available. However, testing for rare 
markers in large, unselected populations always carries the risk of an unfavourable ratio of false-
positive to true-positive results, even if highly specific test methods are used. Therefore, the 
development of consensus guidelines on antibody testing in neurology, which inform physicians who 
are not experts in neuroimmunology about indications for antibody testing, seems warranted. 
General neurology 
Michael Weller 
Over the past decade, neurology has evolved dramatically from a mainly diagnostic—and often 
considered largely academic—speciality into a broad-based clinical discipline with multiple 
ramifications and subspecializations, increasingly focused on innovative and targeted therapeutic 
interventions. The next decade will undoubtedly see even greater changes and challenges for a clinical 
discipline that combines highly specialized, complex interventions with patient care at the community 
level, across a wide range of countries with highly variable health-care systems and resources. 
Some core areas of neurology have seen—and should continue to see—major therapeutic advances. 
Examples include deep brain stimulation and other interventional treatments in Parkinson disease,71 
highly effective (but also potentially dangerous) immune interventions in multiple sclerosis,72 and the 
re-emergence of early multidisciplinary intervention, as well as an evolving area of 
neurorehabilitation, in stroke.73,74 Other areas with a bright future include those where neurology is 
working closely with neighbouring disciplines, hopefully more often in a cooperative than a 
competing fashion. In dementia, for example, neurologists are collaborating with psychiatrists and 
geriatric specialists to determine how to distribute the workload of clinical research, intervention and 
care,75 and how to prepare our ageing societies for this major socioeconomic challenge. Neuro-
oncology is a prototypical multidisciplinary discipline, in which we anticipate major advances in 
technical (in particular, neurosurgical) and immunological interventions.76 
Future challenges for the neurology field include a balanced focus on research, education and patient 
care, and the inevitable re-definition of the main duties of neurologists. We need to evaluate the 
importance of clinical examination skills, and technical expertise in neurology-associated techniques, 
such as ultrasound, EEG and electroneuromyography. In addition, we must weigh up the costs and 
benefits of the increasing repertoire of diagnostic resources. 
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